Eric Molho, MD
Neurology · Albany, NYNPI 1427042399
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,393 of the $43,587 with a category attached, or 81.2%. Neurocrine Biosciences, Inc. accounts for 81.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $18,239 and has fallen 90.1% since, to $1,800 in 2024. Among neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $1037.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$36K
- Acadia Pharmaceuticals Inc$3K
- Lundbeck LLC$2K
- Amneal Pharmaceuticals LLC$2K
- UCB SA$570
- Stryker$97
- plus $79 from 1 others
Across 94 payments — averaging $3084.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$139K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66K
- AbbVie$29K
- Biohaven Pharmaceuticals, Inc.$24K
- Biogen$21K
- Biohaven Pharmaceutical Holding Company Ltd.$10K
- plus $245 from 1 others
What the payments were for
- Consulting fees$5,39012%
- Speaking & faculty fees$35,39381%
- Travel & lodging$2231%
- Food & beverage$1,0652%
- Education$1,5173%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 31 | $35,529 |
| Acadia Pharmaceuticals Inc | 6 | $3,338 |
| Lundbeck LLC | 1 | $2,475 |
| Amneal Pharmaceuticals LLC | 1 | $1,500 |
| UCB SA | 1 | $570 |
| Stryker | 1 | $97 |
| Sanofi | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,587 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 18 | $532,309 |
| IngrezzaValbenazine Tosylate | 34 | $279,230 |
| NuplazidPimavanserin Tartrate | 33 | $191,200 |
| GocovriAmantadine Hcl | 32 | $159,467 |
| XenazineTetrabenazine | 11 | $154,986 |
| RytaryCarbidopa/Levodopa | 36 | $95,766 |
| OngentysOpicapone | 51 | $78,711 |
| InbrijaLevodopa | 23 | $69,645 |
| AustedoDeutetrabenazine | 13 | $67,307 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 443 | $45,557 |
| Droxidopa | 31 | $42,564 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 772 | $34,976 |
| NeuproRotigotine | 19 | $34,491 |
| NourianzIstradefylline | 14 | $25,931 |
| Entacapone | 65 | $15,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $35,529 | $357,94085 claims |
| Acadia Pharmaceuticals IncNuplazid | $3,338 | $191,20033 claims |
| Lundbeck LLCXenazine | $2,475 | $154,98611 claims |
| Amneal Pharmaceuticals LLCRytary | $1,500 | $95,76636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in Albany
- Charles ArgoffAlbany$1.2M
- Stanley PencAlbany$657K
- Angela ApplebeeAlbany$537K
- Krupa PandeyAlbany$433K
- Timothy LynchAlbany$265K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Stephen KriegerNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.